Van Anh Trinh1, Sapna Pradyuman Patel, Wen-Jen Hwu. 1. 1University of Texas M.D. Anderson Cancer Center, Department of Melanoma Medical Oncology, 1515 Holcombe Boulevard, Box 0377, Houston, TX 77030, USA.
Abstract
BACKGROUND: Temozolomide (TMZ) has demonstrated clinical antitumor activity. In the US and the EU, TMZ is licensed for the treatment of glioblastoma multiforme concurrently with radiation followed by a maintenance treatment, and for refractory anaplastic astrocytoma or glioblastoma multiforme. TMZ is also approved for metastatic melanoma in > 20 countries worldwide. OBJECTIVES: To ascertain the safety profile of TMZ. METHODS: Synthesis of evidence from published clinical trials and the investigator's brochure of the manufacture. CONCLUSION: For a cytotoxic cancer-treatment agent, TMZ has an acceptable safety profile. Lymphopenia is common in patients treated with all doses and schedules of TMZ. All patients receiving TMZ should be observed for lymphopenia and potential opportunistic infections, particularly when it is combined with other immune suppressive therapies.
BACKGROUND:Temozolomide (TMZ) has demonstrated clinical antitumor activity. In the US and the EU, TMZ is licensed for the treatment of glioblastoma multiforme concurrently with radiation followed by a maintenance treatment, and for refractory anaplastic astrocytoma or glioblastoma multiforme. TMZ is also approved for metastatic melanoma in > 20 countries worldwide. OBJECTIVES: To ascertain the safety profile of TMZ. METHODS: Synthesis of evidence from published clinical trials and the investigator's brochure of the manufacture. CONCLUSION: For a cytotoxic cancer-treatment agent, TMZ has an acceptable safety profile. Lymphopenia is common in patients treated with all doses and schedules of TMZ. All patients receiving TMZ should be observed for lymphopenia and potential opportunistic infections, particularly when it is combined with other immune suppressive therapies.
Authors: P Gaviani; A Silvani; E Lamperti; A Botturi; G Simonetti; I Milanesi; D Ferrari; A Salmaggi Journal: Neurol Sci Date: 2011-11 Impact factor: 3.307
Authors: Clark Zhang; Elizabeth A Nance; Panagiotis Mastorakos; Jane Chisholm; Sneha Berry; Charles Eberhart; Betty Tyler; Henry Brem; Jung Soo Suk; Justin Hanes Journal: J Control Release Date: 2017-03-07 Impact factor: 9.776
Authors: Pedro Pérez Segura; Miguel Gil; Carmen Balañá; Ignacio Chacón; José Muñoz Langa; María Martín; Jordi Bruna Journal: J Neurooncol Date: 2012-05-20 Impact factor: 4.130
Authors: Catherine R Garcia; Zin W Myint; Rani Jayswal; Chi Wang; Rachael M Morgan; Allison R Butts; Heidi L Weiss; John L Villano Journal: J Neurooncol Date: 2021-11-24 Impact factor: 4.130
Authors: A Gutenberg; C B Lumenta; W E K Braunsdorf; M Sabel; H M Mehdorn; M Westphal; A Giese Journal: J Neurooncol Date: 2013-03-28 Impact factor: 4.130